Amisodin

Phase 1Small molecule

PPRG Science & Technology Co., Ltd.

Amisodin is one of 40 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisRecruiting

Amyotrophic Lateral SclerosisPhase 1

Recruiting

Competition

Competitive Landscape

55 competitors in Amyotrophic Lateral Sclerosis

#DrugCompanyPhaseTrials

Vimpat

UCB

Approved

—2

Nourianz

Kyowa Kirin Co., Ltd.

Enablex

Bosulif

PPrism Pharmaceuticals

Approved

1 5

Qalsody

Biogen

Approved

3 6

Atropen

FFresenius Kabi Taiwan Ltd.

Mirapex

Quinidine Gluconate

WWyeth-Lederle Vaccines

Approved

—9

Transderm Scop

BBaxter Healthcare Corporation

Approved

—10

Rocephin

CConrado Roberto Hoffmann Filho

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

Recruiting·PPRG Science & Technology Co., Ltd.·Phase 1·NCT07221240·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amisodin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amisodin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amisodin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — PRG Science & Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: PPRG Science & Technology Co., Ltd.

Amisodin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Amyotrophic Lateral Sclerosis1 trial

References

Drug Info

Quick Facts

Related News